monitoring patients with cll on ibrutinib-based therapies
Published 13 hours ago • 5 plays • Length 1:13Download video MP4
Download video MP3
Similar videos
-
2:55
a model including cd49d expression to predict outcomes in patients with cll treated with ibrutinib
-
1:45
long-term survival of patients with cll treated with ibrutinib compared to age-matched controls
-
5:03
understanding patient perspectives in cll treatment
-
2:51
genetic markers in patients with early-stage cll treated with ibrutinib: findings from cll12
-
1:47
ianalumab add-on therapy in cll patients receiving ibrutinib
-
1:12
patients with cll on continuous ibrutinib have a life expectancy comparable to healthy individuals
-
9:53
flow cytometry - 4 | cd markers| t cell acute lymphoblastic leukemia & nk cells -- 10 minutes !!!!
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
5:00
gaia/cll13 trial follow-up compares venetoclax combinations in cll
-
3:00
the new criteria for defining high-risk multiple myeloma
-
1:12
pericardial adverse events associated with btkis in cll: insights from two landmark trials
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
2:20
the effect of ibrutinib dose-reduction on outcomes of patients with cll/sll: real-world evidence
-
2:09
real-world incidence of ibrutinib-related cardiotoxicity in cll: insights from the lls registry
-
3:21
enhancing autologous cellular therapy with ibrutinib in cll patients
-
1:18
involving the patient in treatment decisions for cll
-
1:43
the co-administration of bispecific antibodies and car t-cells in cll: an in vivo study
-
1:43
the importance of understanding cellular functionality to develop biological therapies for cll
-
4:29
first-line ibrutinib vs chemoimmunotherapy in cll: a real-world data analysis
-
2:34
sequencing of therapies in patients with r/r cll
-
2:00
obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials